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57 ABSTRACT 
The present invention relates to the use of Coenzyme Q 
in the treatment of slow muscle degeneration, com 
monly known to those of skill in the art so a dystrophy 
or atrophy, and the accompanying cardiac complica 
tions typically identified in such patients. Administra 
tion of Coenzyme Q, and particularly the analog Coen 
zyme Q10 (CoQ10) to humans increases the pumping of 
blood by the heart, and thereby increases tissue oxygen 
eration throughout the body. The net physiological 
effect halts the progression of muscle deterioration and 
improves cardiac function. An overall improvement in 
the quality of life for these human subjects is also ob 
served, said patients reportedly experiencing less fa 
tigue. 
A method for treating human patients with progressive 
muscular dystrophies or the neurogenic atrophies with 
Coenzyme Q10 (CoQ10) specifically disclosed. The 
method is similarly effective for the treatment of any 
form of muscle degeneration or cardiac muscular dys 
function independently. 
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1. 
RESTORATION OF IMPARED CARDAC 
FUNCTION OF PATIENTS WITH DIVERSE 
MUSCULAR DYSTROPHIES BY THERAPY WITH 
COENZYME Q10 
This application is a continutaion-in-part of applica 
tion Ser. No. 06/725,059 filed 04/19/85 now aban 
doned. - 
THE INVENTION 
In January, 1984, (Bender, A. N., Hosipital Medicine, 
p. 95, January, 1984), stated: 
-"The term muscular dystrophy applies to a vari 
able group of disorders-some well defined, and oth 
ers less well defined-categorized by general 
features-. All are primarily diagnosed on clinical 
and genetic grounds, and none of them is treatable at 
the present time. Accurate diagnosis allows realistic 
prognosis, effective rehabilitation, and prevention of 
further cases through genetic counseling.' 
Griggs, M. D., (Supplement II to Circulation Re 
search, vols. 34 and 35) has stated that: 
-"Cardiac disease appears to be the rule rather than 
the exception in virtually every form of hereditary 
and acquired skeletal myopathy.' 
We have made three related discoveries on the ad 
ministration of coenzyme Q10 (vitamin Q10) to patients 
with diverse muscular dystrophies and diverse neuro 
genic atrophies. 
The first discovery was the recognition that, in spite 
of the unknown and variable genetic defects, a patient with 
a form of muscular dystrophy or apatient with a form of 
neurogenic atrophy, could have the impaired cardiac 
function be significantly improved by treatment with 
coenzyme Q10 and not improved by treatment with a 
matching placebo. 
The second discovery was the recognition that all 
patients with eight diverse forms of muscular dystro 
phies and neurogenic atrophies had an increase in their 
impaired cardiac function by treatment with coenzyme 
Q10. It was almost unbelievable that all patients with 
such diverse genetic diseases should all respond by this 
therapy and show a significant increase in the pumping. 
of the blood by their hearts. 
The third discovery was the recognition that the 
impaired cardiac function of many such patients with 
such diverse disease was not only improved, but was 
restored to a normal level of cardiac function. Such resto 
ration was not even considered. It was thought that a 
significant increase of the impaired cardiac function to a 
level below that of the normal range might be possible. 
Reduction to practice may be considered as achieved 
only by the two double blind trials as required by the 
Food and Drug Administration. The two double blind 
trials constitute the Reduction to Practice. 
These three related discoveries constitute a basis for 
the Food and Drug Administration to grant an NDA 
for the clinical use of CoQ10 as an orphan drug for 
months and years of administration and on the basis of 
complete safety. Since such patients have their genetic 
defects for a life-time, they may be safely treated with 
CoQ10 for their life-time. A pharmaceutical company 












for such patients with an NDA from the F&DA, and 
with the protection of a use patent. 
SUMMARY OF THE APPLICATION 
It is known that both cardiac and skeletal muscle 
Contract. 
It is known that the contraction of both cardiac and 
skeletal muscle require energy or "bioenergetics.” 
Skeletal muscle comprises the great mass of the soma 
tic musculature and has well-developed cross striations, 
and does not normally contract in the absence of ner 
vous stimulation. Skeletal muscle is generally under 
voluntary control. 
Cardiac muscle does have cross-striations, but is func 
tionally syncytial in character and contracts rhythmi 
cally in the absense of external innervation owing to the 
presence in the myocardium of pacemaker cells that 
discharge spontaneously. Cardiac muscle contains far 
larger numbers of elongated mitochondria in close 
contact with the fibrils than does skeletal muscle. 
All forms of dystrophy and atrophy involve genetic 
defects and these defects vary widely as evidenced by 
the widely differing symptoms of all of the forms of 
dystrophy and atrophy or myopathy. These genetic 
defects have been studied on skeletal muscle because 
skeletal muscle is available by biopsy in contrast to 
cardiac muscle which is very difficult to obtain from 
living patients for ethical reasons. Consequently, little 
or nothing is known about the differences in genetic 
defects between cardiac and skeletal muscle although 
such differences very probably must exist. 
Coenzyme Q10 is known to provide clinical benefit to 
patients with congestive heart failure but who have no 
muscular dystrophy or atrophy or myopathy. There 
was no basis to predict whether coenzyme Q10 would or 
would not be beneficial to the cardiac dysfunction of 
patients with these muscular diseases and because of the 
great diversity of the genetic defects and the great di 
versity of the clinical symptoms of all these diseases. It 
appeared probable that any clinical usefulness of admin 
istering coenzyme Q10 to such patients would be very 
limited or negative entirely, because of the apparent and 
diverse genetic defects. 
There was no assurance that CoO10 would benefit the 
cardiac function of dystrophic patients. The first dou 
ble-blind and open cross-over trial on the oral adminis 
tration of coenzyme Q10 (CoQ10) to 12 patients with 
progressive muscular dystrophies and neurogenic atro 
phies was conducted. These diseases included the Du 
chenne, Becker and, limb-girdle dystrophies, myotonic 
dystrophy, Charcot-Marie tooth disease and Welander 
disease. Cardiac function was noninvasively and exten 
sively monitored by impedance cardiography. Solely 
by significant change or no change in stroke volume 
and cardiac output, all eight patients on blind CoQ10 
and all four on blind placebo were correctly assigned, 
p (0.003. The monitoring of cardiac function of these 
12 patients before the trial revealed degrees of impaired 
cardiac function ranging from relatively severe to defi 
nite to low impairment. 
It was discovered that the oral administration of 
CoQ10 gave a substantial and surprising improvement to 
the impaired cardiac function. This initial double blind 
trial was only on 12 patients, 8 on blind CoQ10 and 4 on 
blind placebo. It was apparent that even though the 
cardiac response was significant, p<0.003, the two 
groups of 8 patients and 4 patients, respectively, had too 
few patients to support biologically the discovery of a 
4,885, 167 
3 
positive clinical benefit to cardiac function, when the 
possibility of such a discovery was so questionable. In a 
second double blind trial with a total of 15 similar pa 
tients, 8 on blind CoQ10 and 7 on blind placebo, the 
discovery was confirmed. All 8 patients on blind CoO10 
showed significant cardiac improvement and all 7 on 
blind placebo were negative. The results of the two 
trials when combined involved 16 patients on blind 
CoQ10 and 11 patients on blind placebo which is suffi 
cient to document the discovery that CoQ10 benefits the 
cardiac function of dystrophic patients. 
Two more discoveries resulted from this research. 
The second discovery was that CoQ10 therapy benefited 
eight diverse forms of dystrophy and myopathy which 
is remarkable since these eight dystrophies and myopa 
thies are genetically different and reveal very different 
clinical symptomatology including early death for the 
Duchenne dystrophy (up to 20 years of age) and dec 
ades of life for other dystrophies such as the Charcot 
Marie tooth disease. 
The third discovery from the second double blind 
trial was that the cardiac functions of some of the pa 
tients were restored to a normal range. A higher dosage 
and longer treatment could likely increase the cardiac 
function of even more of the patients. 
Consequently, the oral administration of coenzyme 
Q10 to patients with very diverse forms of muscular 
dystrophy and neurogenic atrophy is very useful, be 
cause the resulting improved cardiac function definitely 
benefits the health through more blood providing more 
oxygenation throughout the body. Since CoO10 is ex 
ceptionally safe, this therapy for patients with such 
disease may be used as long as required or even for a 
life-time. 
BACKGROUND ON INVENTION STUDES 
Coenzyme Q in Mice with Genetic Dystrophy 
Lack of Significance of Animal Dystrophy. There 
have been many studies involving mice based on the 
biochemistry of CoQ, but there is no absolute certainty 
of the relationship of a genetic disease in mice in com 
parison with that of man. It hardly seems that the ge 
netic defects of mice and man are truly identical, al 
though there can be superficial similarities. One fact 
proving a difference rather than identity is the existance 
of CoQ9 in mice and CoQ10 in man. Obviously, a prom 
ising benefit for mice with a genetic disease does not 
guarantee a response in man by the same treatment. 
An account of studies with CoQ in mice with genetic 
dystrophy are as follows. 
Michelson, A. M., Russel, E. S., and Pinckey, K. H., 
(Proc. Natl. Acad. Sci. USA 41, 1079 (1955)), described a 
mutation of mice that have a muscular degeneration 
which resembles progressive muscular dystrophy in 
humans. West, W. T., Meier, H., and Hoag, W. G., 
(Ann, N.Y. Acad. Sci, 138, 4 (1966)) considered that 
dystrophy occurred as a spontaneous autosomal muta 
tion in mice 129/Re which causes muscular weakness, 
atrophy and a reduced life-span. These mice showed 
clinical, histological, and physiological similarities to 
juvenile progressive psudohypertrophic and myotonic 
dystrophy of man, Erb's dystrophy and, except for the 
difference in inheritance, the Duchenne dystrophy. 
Dystrophic mice which were treated with hexahy 
drocoenzyme Q4 (H6CoQ4) improved so that severely 
dystrophic animals responded and were able to walk 
using all their legs; (Farley, T. M., Scholler, J., and 











(1966)). A study of the biosynthesis and levels of CoQ in 
these mice indicated a possible genetic defect in the 
biosynthesis of p-hydroxybenzoic acid (HBA) from 
tyrosine rather than a defect between CoQ and HBA or 
some other defect involving CoQ; (Nilsson, L. G., Far 
ley, T. M., Scholler, J., and Folkers, K., Arch. Biochem. 
Biophys. 123,422 (1968)). In later studies, these dystro 
phic mice were treated with H5CoO4 when they be 
came unable to use their hind limbs. After two weeks of 
therapy, their improved condition allowed the use of 
one or both hind legs, and survival was four times that 
of control mice; (Scholler, J., Farley, T. M., Folkers, 
K., Intern. J. Vitamin Res. 38,369 (1968)). This dystro 
phy was studied as a possible coenzyme Q dependency 
state; (Ho, L., Folkers, K., Abstract for 27th Meeting of 
Southwest Region of American Chemical Society 88, 38, 
San Antonio, Tex., December, 1971). Determination of 
the specific activities of the succinate dehydrogenaseco 
enzyme Q9 reductase of hearts and hind leg muscles of 
dystrophic mice revealed a deficiency, p<0.01, of the 
intrinsic CoQ9; (Littarru, G. P., Jones, D., Scholler, J., 
and Folkers, K., Biochem. Biophys. Res. Commun. 41(5), 
1306 (1970). When these dystrophic mice were cura 
tively treated with CoQ7, instead of the intrinsic CoQ9, 
in the fifth month of their life span of eight months, 
survival increased to twice that of the control group. 
CoQ7 was isolated from the mitochondria of the hearts 
and hind legs of the orally treated mice, substantiating 
that the CoQ7 was substituting for and correcting the 
deficiency of CoQ9 in the dystrophy. 
Studies with Coenzyme Q on Patients with Genetic 
Muscle Disease. 
Significance of Open Very Limited Trials. The ex 
ploratory trials of administering H5Co04 to humans 
with dystrophy were negative. Couch, J. R. and Folk 
ers, K. (Biomedical and Clinical Aspects of Coenzyme Q, 
Vol 3, K. Folkers and Y. Yamamura, eds., Elsevier/- 
North Holland Biomedical Press, Amsterdam, 257-266, 
(1981)) administered CoO10 to 2 adults with limb-girdle 
dystrophy and recorded a transient small improvement 
in strength, and which appeared to slow deterioration. 
Such observation is clinically meaningless because the 
transient small improvement could have been the varia 
tion in the symptoms of the disease which are known to 
occur with the limb-girdle dystrophy and which is not 
as fatal as Duchenne. It is well known that the symp 
toms of this dystrophy decrease and improve with time 
and independent of any treatment. 
Folkers, K., Baker, L., Richardson, P. C., Shizukui 
shi, S., Takemura, K., Drzewoski, J., Lewandowski, J., 
Ellis, J., (Biomedical and Clinical Aspects of Coenzyme Q, 
Vol. 3, K. Folkers and Y. Yamamura, eds., Elsevier/- 
North Holland Biomedical Press, Amsterdam, 399-412 
(1981)) reported the administration of CoQ10 to a single 
adult with a late onset form of muscle disease and ob 
served that the expected deterioration appeared to be 
retarded. Again, such observation is clinically meaning 
less, because one does not know what the rate of deteri 
oration would have been in the absence of administra 
tion of CoQ10. 
Again, the patient with this mild dystrophy which is 
not fatal until late decades is known to have decreased 
symptoms and increased symptoms over time without 
any treatment. 
Danowski, T. S., Wissinger, H. A., Hohmann, T. C., 
Gerneth, J. A., Folkers, K., Vester, J. W., and Fisher, 
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E. R., (Archives of Physical Medicine and Rehabilitation 
52, 193 (1971)), clinically studied the administration of 
H5Co04 in the muscular dystrophies and in myotonia 
dystrophica, but no clinical benefit was observed in the 
human psudohypertrophic muscular dystrophy. Sovik, 
O., Stromme, J., Folkers, K., (Acta. Paediat. Scand. 60, 
428 (1971), administered H6CoQ4 to four cases of Du 
chenne muscular dystrophy. No improvement in mus 
cular strength was observed, but there was a statisti 
cally significant decrease of CPK and aldolase for one 
boy. Danowski, T. S., Folkers, K., Wissinger, H. A., 
Hohmann, T. C., Gerneth, J. A., and Vester, J. W., 
(Journal of Pharm. Sciences 60, 640 (1971)) investigated 
the administration of H6CoQ4 to 19 boys with pseudo 
hypertrophic muscular dystrophy of the Duchenne 
type. A battery of clinical and laboratory indices were 
monitored. No beneficial change was observed. The 
failure of H6CoQ4 to elicit a clinical effect in humans, 
but to do so in mice, might be partly explained by bio 
chemical data that showed H6CoQ4 has only about 
10-15% of the activity of CoQ10 for DPNH-oxidase; 
(Lenaz, G., Daves, G. D., Folkers, K., Arch. Biochem. 
Biophys, 123,539 (1968)), by dosage, species difference 
and protocol. Folkers, K., Littarru, G. P., Nakamura, 
R., and Scholler, J., (Internat. J. Vit Nutr. Res. 42, 139 
(1972)) used new enzyme methodology on muscle biop 
sies of dystrophic patients, and found that the succinate 
dehydrogenase-coenzyme Q10 reductase was inactive 
for some patients and poorly active for others, which 
might result in no or poor response to treatment with 
CoQ. However, administration of CoQ and placebo 
appropriately reduced CPK. They emphasized the de 
sirability of treatment with CoQ of pre-clinical stages of 
dystrophy, and Folkers, K., Nakamura, Littarru, G. P., 
Zellweger, H., Brunkhorst, J. B., Williams, C.Y., Lang 
ston, J. H., (Proc. Natl. Acad. Sci 7105), 2098-2102 
(1974)) did administer H5Co04 and CoQ7 to children 
with pre-clinical dystrophy. Extensive monitoring of 
enzyme levels revealed significant reductions of CPK. 
Couch, J. R., and Folkers, K., (Biomedical and Clinical 
Aspects of Coenzyme Q, Vol. 3, K. Folkers and Y. 
Yamamura, eds., Elsevier/North Holland Biomedical 
Press, Amsterdam, 257-266, (1981) administrated 
CoQ10 to two adults with limb-girdle dystrophy, and 
recorded a transient small improvement in strength, 
which appeared to slow deterioration. Folkers, K., 
Baker, L., Richardson, P. C., Shizukuishi, S., 
Takemura, K., Drzewoski, J., Lewandowski, J., Ellis, 
J., (Biomedical and Clinical Aspects of Coenzyme Q, Vol. 
3, K. Folkers and Y. Yamamura, eds., Elsevier/North 
Holland Biomedical Press, Amsterdam, 399-412 (1981)) 
reported the administration of CoQ10 to an adult with a 
late onset form of muscle disease for six years, and the 
expected deterioration of physical competence was 
markedly retarded. 
Association of Muscular Disease with Cardiac Disease. 
Welsh, J. D., Lynn, T. N., Haase, G. R., (Archives of 
Internal Medicine 112, 199-206 (1963)) reported upon 
the cardiac findings in 73 patients with muscular dystro 
phy, including the Duchenne, the limb-girdle, and the 
facioscapulohumeral forms, and patients with dystro 
phia myotonica. Zellweger, H., Durnin, R., Simpson, J., 
(Acta. Neurol. Scandinay, 48, 87 (1972)) evaluated the 
electrocardiograms for various muscular dystrophies. 
Kuhn, E., Fiehn, W., Schroder, J. M., Assmus, H., and 
Wagner, A., (Neurology 29, 1144-1149 (1979)) described 















dystrophy. Reeves, W. C., Griggs, R., Nanda, N. C., 
Thomson, K., Gramiak, R., (Arch. Neurol. 37,273-277 
(1980) evaluated echocardiographic abnormalities in 
24 subjects with Duchenne's dystrophy and 29 with 
myotonic muscular dystrophy. A significant incidence 
of cardiac abnormalities were demonstrable by echocar 
diography. Hopkins, L. C., Jackson, J. A., Elsas, L. J., 
(Ann. Neurol. 10, 230-237 (1981)) found that Emery/. 
Dreifuss humeroperoneal muscular dystrophy may be 
associated with a potentially lethal cardiac arrhythmia. 
Goldberg. S.J., Stern, L. Z., Feldman, L., Allen, H. D., 
Sahn, D. J., Valdes-Cruz, L. M., (Neurology 32, 
1101-1105 (1982)), by a computerized study, found 
ventricular abnormalities as Duchenne patients develop 
severe cardiac disease. Hawley, R. J., Gottdiener, J. S., 
Gay, J. A., Engel, W. K., (Arch. Intern. Med. 143, 
2134-2136 (1983) evaluated 30 patients with myotonic 
dystrophy and the incidence of substantial cardiac in 
volvement. Durnin, R. E., Ziska, J., Chandramouli, B., 
(Journal of Iowa Medical Society, (1969)), found that 
80% of 52 patients with progressive muscular dystro 
phy had abnormal electrocardiograms. 
The association of cardiac disease with muscular 
disease is established. 
Mitochondrial Myopathies. 
Carafoli, E., Roman, I., (Molecular Aspects of Medi 
cine 3, 295 (1980)) and Morgan-Hughes, J. A., (Ad 
yanced Medicine 19, K. B. Saunders, ed., Pitman Pub 
lishers Ltd., London, 243-260 (1983)), identified defi 
ciencies of the mitochondrial respiratory chain or its 
associated phosphorylation system in muscle mitochon 
dria from myopathies in man. Since CoQ10 is an estab 
lished constituent of the mitochondrial respiratory 
chain, these studies are basic to elucidation of human 
muscle disease. 
Morgan-Hughes, J. A., Hayes, D. J., Clark, J. B., 
Cooper, J. M., (Biomedical and Clinical Aspects of Coen 
zyme Q, Vol. 4, K. Folkers and Y. Yamamura, eds., 
Elsevier/North Holland Biomedical Press, Amsterdam, 
417-424 (1984)) conducted a most important study on 
isolated muscle mitochondria from 18 patients with 
myopathies. The respiratory activity, cytochrome con 
tent, and activities of several citric acid cycle enzymes 
were measured. The purity and integrity of the mito 
chondrial samples were documented. In ten cases of 
myopathy, the defect was in the first respiratory com 
plex. In five cases, the deficiency was localized to the 
coenzyme Q-cytochrome bc1 reductase complex. Respi 
ratory rates were either low or not demonstrable with 
NAD-linked substrates or with succinate. Complex III 
deficiency was also monitored. 
Measurement of Cardiac Function of Patients with 
Muscle Disease 
All of the background research on the detection and 
some measurement of impaired cardiac function in pa 
tients with muscular disease only demonstrated an asso 
ciation of cardiac disease with muscular disease. Not 
one of those past studies involved the testing of any 
thing to improve an impaired cardiac function. The 
conventional methods (echo cardiography, etc.) in car 
diology of measuring cardiac function are essentially 
qualitative procedures useful for confirmation of diag 
nosis. These procedures are not sufficiently reliable and 
quantitative to monitor accurately over months of time 
cardiac function to determine whether the administra 
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tion of any therapeutic agent is or is not effectively 
benefiting cardiac function. 
Impedance cardiography offers a noninvasive, repro 
ducible and acceptably quantitative measurement to 
monitor cardiac function over months of time. This 
technique has been described by Kubicek, W. G., Kar 
negis, J. N., Patterson, R. P., Witsoe, D. A. and Matt 
son, K. H., (Aerospace Med. 37, 1208-1212, 1966). 
Therefore, impedance cardiography is the instrumenta 
tion of choice to monitor cardiac function of patients 
with muscle disease over months of time as coenzyme 
Q10 is orally administered. 
General Method (The First Double Blind Trial) 
The selected patients, as volunteers, were monitored 
by four to six impedance cardiographic measurements 
during a 30 to 75-day control period. The instrument 
consisted of a cardiograph, a computer and a printer 
purchased from Surcom, Inc., 4180 Edmond Blvd., 
Minneapolis, Minn. 55406. The double-blind treatment 
was with daily capsules of CoQ10 (33 mg CoQ10/cap 
sule, t.i.d.) and a matching placebo. Stroke volume, 
cardiac output and heart rate were monitored for a 
minimum of three measurements/month during of each 
month of a three-month period. Multiple measurements 
allowed statistical calculations. When there was a sus 
tained clinical response judged by the cardiac output 
and or in the stroke volume, with statistical significance 
of p <0.01-p (0.001 during a three-month period, a 
blind assignment of CoQ10 was made. When cardiac 
output and stroke volume had not significantly 
changed, not even by p <0.05 during a blind treatment 
period of three months, placebo was assigned, and the 
patients were then provided with open CoQ10 on a 
crossover basis. 
The blood levels of CoQ10 were determined essen 
tially by the method of Kishi, T., Okamoto, T., 
Kanamori, N., Yamagami, T., Kishi, H., Okada, A., and 
Folkers, K., (Biomedical and Clinical Aspects of Coen 
zyme C, Vol. 3, K. Folkers and Y. Yamamura, eds., 
Elsevier/North Holland Biomedical Press, Amsterdam, 
67-78 (1981), during the control and the blind periods 
of treatment. These data from the blind treatment per 
iod were not made available until after assignments of 
the patients to treatment with CoQ10 or placebo were 
made, because knowledge of blood data prior to the 
blind assignments would have allowed assignments on 
the basis of blood data alone. 
Results of the First Double Blind Trial 
Blood Levels of CoQ10. The control blood levels of 
CoQ10 ranged from 0.50-0.84, which are lower than a 
mean plasma (only) level of 0.79-0.23 g/ml of pre 
sumably normal subjects; Kishi, et al., 1981 (31). These 
differences between levels in muscle disease and normal 
may be numerically small, but bioenergetically high. 
After oral CoO10, the increased blood levels ranged 
from 1.11-2.93 ug/ml. 
Cardiac Function (Objective). Table I contains the 
data on the cardiac function of the patients during the 
double-blind trial with capsules of CoQ10 and a match 
ing placebo, and the crossover from blind placebo to 
open CoQ10 at the time of assignment and decoding. 
Table II contains the data on assignments, code and 
CoQ10-blood levels. 
For a total of 12 patients, seven had progressive mus 
cular dystrophies including the Duchenne, Becker, and 












phies including the Charcot-Marie Tooth disease, and 
the Wohlfart-Kugelberg Welander disease. 
Before decoding and the availability of the blood 
data, eight of the twelve patients were assigned CoQ10 
and the remaining four were assigned placebo. Decod 
ing revealed that not one mistake of assignment had 
been made, p<0.003. 
The patients who initially received blind CoQ10 had 
the Duchenne and Becker dystrophies and Welander's 
disease and the patients initially receiving blind placebo 
had the limb-girdle and myotonic dystrophies and 
Charcot-Marie Tooth disease. All four patients initially 
receiving blind placebo were then treated for 3 months 
with open CoQ10, and showed statistically significant 
increases in cardiac function. 
Of the eight patients who were first treated with blind 
CoQ10, two resigned from the study before the cross 
over period. Five.of the six who were first treated with 
blind CoO10 maintained improved cardiac function dur 
ing crossover with open CoQ10, and one of these five, 
L. R., with Duchenne dystropy, age 7, responded better 
(p<0.001) in the 4th-6th month on CoQ10 than in 
months 1-3 (p<0.054 for S.V.). The one patient, H. M. 
K. with Charcot-Marie Tooth disease, 63 years, re 
lapsed to the impaired control level of cardiac function 
on placebo, after significant response, p<0.001, to blind 
CoQ10. The control stroke volume of all 12 patients 
ranged from 29 to 100 ml/beat, but even the one patient 
(Becker's dystrophy) with a stroke volume of 100-16 
increased to 1309 (p<0.001) during CoQ10 treatment. 
Stroke volume, in ml. of blood pumped/heart beat, is 
appraised as a prime criterion because it is independent 
of the heart rate, and impedance cardiography is supe 
rior in allowing beat-by-beat data. The cardiac outputs 
for all 12 subjects ranged from 3.1 to 7.2 L/min. The 
subject with CO of 7.2-1.6 (Becker's dystrophy) in 
creased to 9.0-0.4 (p<0.001) on CoQ10. 
Introduction to Second Double Blind Trial 
Coenzyme Q10 (CoQ10) is essential in the bioenerget 
ics of the human cell and is one of the factors that sus 
tains muscle activity. CoO10 is lipid-soluble and is pres 
ent in the mitochondrial membrane and is an intermedi 
ate between NADH and succinate dehydrogenase and 
cytochrome b in the respiratory chain of human muscle 
tissue. (1,2). Folkers et al. (3) and Kamikawa et al. (4) 
have documented that coenzyme Q10 is essential in the 
maintenance of normal heart function by regulating the 
energy metabolism in the myocardium. Diseases of the 
human heart are often correlated with a decrease in the 
levels of myocardial CoO10 (5,6). Many investigators 
have reported the association of cardiac disease with 
muscular disease (7, 8, 9, 10, 11, 12, 13, 14). Our first 
double blind study (15) showed the impaired myocar 
dial function of patients with muscular dystrophy im 
proved on CoO10 therapy, and there was also observed 
improved physical performance. The aim of this present 
study was to extend and to confirm our initial double 
blind trial on the administration of coenzyme Q10 to 
patients with muscular dystrophy. 
General Method (Second Double Blind Trial) 
Fifteen muscular dystrophy patients (Table III), as 
volunteers, were monitored by four to six impedance 
cardiographic measurements during 14 to 96-day con 
trol periods. Cardiac performance was determined as 
stroke volume (SV) and cardiac output (CO) and was 
recorded at rest (16). The impedance cardiography 
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provides a noninvasive, reproducible and acceptably 
quantitative measurement and is known to correlate 
with angiographic, dilution or ultrasound procedures to 
measure cardiac function (17, 18). The double blind 
treatment was with daily capsules of CoQ10 (33 mg of 
CoQ10 per capsules, ti.d.) and a matching placebo. 
Heart rate, SV and CO were monitored for a minimum 
of three measurements per month during each month of 
the investigation period. Multiple measurements al 
lowed statistical calculations. A sustained clinical re 
sponse, judged by the cardiac output and/or the stroke 
volume with statistical significance of p <0.01 to 
p(0.001 during observation in the blind period allowed 
an assignment of CoQ10 to be made. When cardiac out 
put and stroke volume had not significantly changed 
during the blind treatment period, placebo was as 
signed, and the patients were then provided with open 
CoQ10 on a crossover basis. Patient 8 with Becker's M. 
D. was a male, 14 years, who was obviously growing, 
and showed a modest increase in cardiac function on 
placebo and a greater increase on CoO10. 
The blood levels of CoQ10 were determined (19) 
during the control and blind periods of treatment. 
Blood data during treatment were not made available 
until after assignments of the patients to treatment with 
CoQ10 or to placebo were made, because knowledge of 
blood data prior to the blind assignments would have 
allowed assignments on the basis of blood data alone. 
Statistic comparison of results were obtained using the 
Student-t test. 
Results of the Second Double Blind Trial 
The cardiac function of all 8 patients treated with 
CoQ10 during double blind and all 7 placebo patients 
during crossover improved significantly (Table III). 
The cardiac performance of 6 patients on blind placebo 
did not significantly improve. 
Of the 15 patients, 8 had cardiac functions at rest 
which were lower than the low value of a normal range 
(20). Four (having limb-girdle, Becker's and Charcot 
Marie Tooth diseases) of these 8 had cardiac functions 
on therapy which were restored to a normal range. 
However, each of the 15 patients had a significantly 
improved cardiac function on therapy. 
Patient #8, a fourteen year-old boy with Becker's 
muscular dystrophy, improved somewhat by SV and 
CO in the blind placebo period, but improved far more 
during crossover on CoQ10. His improved cardiac per 
formance in the placebo period was apparently caused 
by his markedly increased growth. His degree of 
growth was the basis of assignment of placebo. Two 
children (patients #1 and #15) did not show any 
marked body growth during the time of the study. 
All assignments of the patients to treatment with 
CoQ10 or placebo were made correctly (Table IV). The 
control blood levels of CoQ10 ranged from 0.58 to 1.17 
ug/ml and increased more than two-fold during the 
CoQ10 treatment period (Table II). Compliance is diffi 
cult to know, and it is doubtful that all patients had 
perfect compliance, which would relate to the blood 
levels of CoQ10. 
Our first double blind trial (15) was conducted with 
12 patients, and this second trial was with 15 patients. 
Not a single mistake was made in assignment of treat 
ment with CoQ10 or placebo during the two double 














Cardiac Performance. Muscular dystrophies are gen 
erally regarded as involving genetic defects and as in 
curable diseases. However, therapeutic benefit is possi 
ble for the sequelae of the genetic defects. 
Cardiac involvement in the form of cardiomyopathy 
is a well known essential feature of muscular dystro 
phies. Ultrastructural studies have demonstrated that 
cardiac changes are similar to those detected in the 
"dystrophic' skeletal muscle (8, 9). The diagnosis of 
cardiac involvement was also based on the demonstra 
tion of typical electrocardiographic changes, namely 
tall R waves in V1, with R/S ratio > 1, and deep and 
narrow Q-waves in limb leads and over the left lateral 
precordium. Physical and radiographic examination of 
the heart appears less specific, because of the frequent 
presence of thoracic deformities and high diaphragms. 
In recent years, echocardiography has gained increas 
ing recognition, also in the preclinical state, in the 
noninvasive assessment of functional and anatomic car 
diac changes. In the present study, we have used impe 
dance cardiography to evaluate cardiac performance. 
Impedance cardiography is a noninvasive, reproducible 
and is a quantitative measurement to monitor cardiac 
function over months of time. This technique has supe 
riorities, as evaluated by Baker and Mistry (21), in com 
parison with other techniques to measure cardiac func 
tion in the study of CoQ10 and dystrophy. 
Mitochondrial Myopathies. Over the past decade, 
there have been many studies on the treatment of differ 
ent cardiac diseases with CoQ10 (22, 23, 24, 25, 26, 27). 
Carafoli et al. (28) and Morgan-Hughes et al. (29, 30) 
identified deficiencies in the mitochondrial respiratory 
chain or its associated phosphorylation system, in mus 
cle mitochondria from myopathies in man. In 1986, 
Sholte et al. (31) found that the most frequently discov 
ered defects in human mitochondria of patients with 
muscular disease are multiple defects in oxidative phos 
phorylation, NADH-CoQ reductase, CoQ10-cyto 
chrome bc1, cytochrome aa3, multiple respiratory chain 
defects, loose coupling and adenine nucleotide translo 
case. The rationale of this trial was based on known 
myocardial myopathies which involved respiratory 
enzymes, the known presence of CoQ10 in respiration, 
and prior clinical data on CoQ10 and dystrophy. The 
results show improved cardiac function by double blind 
CoQ10 therapy for these dystrophic patients and are 
identical to the results of the prior study (15). 
Conclusion. Therapy with CoQ10 is oral, without any 
side effect, and may be administered for the lifetime of 
such patients with muscular dystrophy. At present, 
there is no therapy for such patients. The improved 
cardiac performance of such patients is apparently es 
tablished. 
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Sex, Age Diagnosis C. B. Oth 
1. M. B. Limb-Girdle 48 60 300 
F 45 Dystrophy 
2 L. R Duchenne 75 70 270 
M7 Dystrophy 
3 D. M. Myotonic 50 61 80 
M 16 Dystrophy 
4 K. A. C. Duchenne 29 13 172 
M7 Dystrophy 
5. H. L. D. Limb-Girdle 37 122 110 
F 39 Dystrophy 
6. J. L. J. Becker's 29, 180 
M25 Dystrophy 
7. D. L. K. Becker's 60 150 
M37 Dystrophy 
8. W. P. Charcot-Marie 28 121 90 
F 69 Tooth Disease 
9. H. M. K. Charcot-Marie 32 9. 96 
F 63 Tooth Disease 
Functional data; Mean S.D. 
a, Cardiac Output (CO), L/min. 
b, Stroke Volume (SV), ml. 
(days) c, Heart Rate (HR), beats/min. 
C, Control B, Double Blind O, Open 
a, 5.2 - 0.3 5.0 - 0.6 n.s. 6.4 - 0.4 p < 0.00 
b, 57 - 7 60 - 1 n.s. 69 - 4 p < 0.001 
c, 96 - 8 84 - 11 - 98.3 - 
a, 3.1 it 0.4 3.4 it 0.2 n.s. 4.0 - 0.1 p < 0.001 
b, 30 - 5 34 - 7 p < 0.5 37 - 8 p < 0.001 
c, 102 - 8 101 - 9 - 107 7 -- 
a 3.3 - 0.4 3.4 - 0.2 n.s. 4.2 - O.S p < 0.001 
b, 29 - 4 30 - 1 m.s. 42 8 p < 0.001 
c, 118 - 6 - 110 - 2 - 101 - 10 - 
a, 4.2 - 0.6 5.2 - 0.2 p < 0.001 4.5 - 0.7 p < 0.001 
b, 38 - 6 48 - 3 p < 0.001 42 - 8 p < 0.001 
c, 108 - 3 107 - 8 - 07 - 4 -- 
a, 6.0 - 0.5 5.7 0.4 n.s. 5.5 - 0.3 l.S. 
b, 79 - 7 72 - 2 n.s. 73 T.S. 
c, 77 - 3 76 - 6 -- 75 - - 
a, 7.2 - 1.6 9.0 - 0.4 p < 0.001 D 
b, 100 - 16 130 - 9 p < 0.001 D 
c, 69 - 4 71 - 4 - 
a, 5.9 - 1.1 6.9 - 1.0 p < 0.001 7.42 - 1.36 p < 0.001 
b, 80 - 12 99 - 16 p < 0.001 106 - 26.63 p < 0.01 
c, 76 + 6 68 - 4 - 70 wn 
a, 5.2 - 0.2 5.7 t 0.2 n.s. 6.3 - 0.8 p < 0.001 
b, 67 - 6 69 - 2 n.s. 85 - 12 p < 0.001 
c, 77 - 3 76 c 3 - 74 - 2 - 
a, 5.3 - 0.8 6.5 - 1.1 p < 0.001 4.6 - 0.4 n.s. E 
b, 71 - 9 89 - 13 p < 0.001 67 - 2 ns. E 




Data on Cardiac Function of Patients 
Functional Data; Mean : S.D. 
Treatment a, Cardiac Output (CO), L/min. 
Duration, b, Stroke Volume (SV), ml. 
Patient - Gays) - Heart Rate (HR), beats/min - 
Sex, Age Diagnosis C. B. Ot C, Control B, Double Blind O, Open 
10, B, H. Charcot-Marie 30 105 a, 4.0 - 0.4 4.2 t 0.6 n.s. D 
M31 Tooth Disease b, 61 - 8 70 - 11 p < 0.001 D 
c, 67 - 4 60 - 6 - 
11. M. D. Charcot-Marie 45 90 300 a 5.0 - 0.3 5.3 is 0.2 m.s. 6.3 0.6 p < 0.001 
F 63 Tooth Disease b, 68 - 8 76 - 5 p < 0.001 83 - 5 p < 0.001 
c, 74 - 6 O 3 i.S. 75 - 4 
2. C.S. Welander 43 120 180 a, 3.9 - 0.5 4.5 + 0.5 p < 0.001 4-6 - 0.5 p < 0.001 
F 49 Disease b, 68 it 6 84 - 9 p < 0.001 74 - 11 p < 0.001 
c, 57 - 6 54 - 5 -- 625 O 
C as Control, 
B = Blind, coded period of study, 
O = Open period of study 
D = Resigned from study 
E = Crossover placebo period 
TABLE 
Double Blind and Open Trial Data and Blood Data 
CoQ10 Blood Levels 
Patient Double Blind Average ug/ml 
Sex, Age Assignment Code Control Blind Open 
1. M. B.; F 45 Placebo Placebo 0.63 0.61 1.40; CoQ10 
2. L. R.; M 7 CoQ10 CoQ10 0.62 i.11 1.24; CoO10 
3. D. M.; M 16 Placebo Placebo 0.58 0.61 1.32; CoO10 
4. K. A. C.; M7 CoQ10 CoO10 0.50 1.94 1.47; CoQ10 
5. H. L. D.; F 39 Placebo Placebo 0.68 0.63 1.76; CoQ10 
6. J. L. J.; M25 CoO10 CoQ10 0.71 1.22 - 
7. D. L. K.; M 37 CoQ10 CoQ10 0.55 1.16 1.13; CoQ10 
8. W. P.; M 69 Placebo Placebo 0.84 0.77 2.13; CoQ10 
9. H. M. K.; F 63 CoQ10 CoQ10 0.82 2.93 1.12; P 
10. B. H.; M 31 CoO10 CoQ10 0.59 2.09 - 
11. M. D.; F 63 CoQ10 CoQ10 0.68 1.96 1.43; CoO10 
12. C. S.; F 49 CoQ10 CoQ10 0.78 1.58 2,03; CoQ10 
TABLE III 
MUSCULARDYSTROPHY PATIENTS 
DETAILS OF DATAON CARDAC FUNCTION 
Functional Data; Mean S.D. 
A. Cardiac Output (CO), L/min 
Treatment B. Stroke Volume (SV) ml/beat 
Patient, (Days) C. Heart Rate (HR) beats/min 
No, Sex, Age Diagnosis Ctrl DB Oc Controla Double Blind Open Q10, crossover. 
1. J. A. Duchenne M.D. 96 OS 82 A. S.3 0.7 A 5.6 0.7 S. A. 6.6 0.8 p (0.001 
(M,8) B. 65 - 9 B. 66 16 S. B. 807 p(0.001 
C. 809 C, 86 - 10 C. 87 8 ar 
2. J. P. B. Limb-girdle M.D. 78 102 862 A. 5.3 - 0.3 A, 5.5 - 0.3 a.s. A. 5.8 it 0.7 p <0.001 
(M43) B. 73 - 5 B. 755 S. B. 73 10 S, 
C. 77 - 2 C, 3 4 C. 79 5 o 
3. D. C. Fascioscapulo- 30 186 69 A. 7.9 0.7. A. 8.1 - 1.4 n.s. A, 11.1 - 4 (0.001 
(M,33) humera M.D. B. 29 B. 32 8 S. B. 168 - 21 pC0.001 
C. 64 - 4 C, 63 10 C. 657 
4. D. H. Charcot-Marie- 20 26 34 A, 7.9 0.8 A, 8.1 - 0.7 m.s. A. 11.8 - 2.3 p <0.001 
(M,54) Tooth M.D. B. 126 - 14 B, 129 - 10 m.s. B. 186 - 31 p.<0.001 
C. 62 - 1 C. 61 - 2 C. 78 4 
S. P. K. Limb-girdle M.D. 34 481 890 A, 4.5 + 0.4 A. 5.4 - 0.4 p(0.001 A. 6.2 - 0.5 p <0.001 
(F,31) B. 469 B. 59 - 7 p(0.001 B. 694 p(0.001 
C. 999 C. 91 - 5 m C. 895 O 
6. M. R. Charcot-Marie- 14 158 68 A. 9.1 - 0.8 A. 12.2 - 1.7 p(0.001 A. 11.9 it 1.4 p <0.001 
(M,27) Tooth M.D. B. 135 - 17 B. 188 - 14 p <0.00 B. 195 - 11 p.<0.001 
C. 68 8 C. 64 S - C. 62 6 
7. M. R. Hypotonic 24 118 260 A. 6.9 - 0.6 A. 7.5 - 0.1 p <0.001 A. 10.4 it 2.1 p<0.001 
(F,33) congenitale B, 82 6 B. 95 - 5 p<0.001 B. 124t 19 p <0.001 
C. 84 7 C. 79 - 5 C, 83 - 6 
8. T. A. W. Becker's M.D. 6 131 124 A. 6.1 - 0.5 A. 7.3 - 0.7 p(0.001 A. 9.7 it 1.7 p <0.001 
(M,14) B. S7.2 1 B. 74 7 p(0.001 B. 97 - 15 p C0.001 
C, 104 - 2 C. 99 4 C. 99 - 3 -- 
9, J. M. Charcot-Marie- 30 120 359 A. S.0 - 0.9 A. S.5 0.9 m.s. A, 6.6 - 1.7 p <0.001 
(F,58) Tooth M.D. B. 609 B. 57. 9 S. B, 70 16 p(0.001 
C. 84 - 2 C. 98 : 6 C. 935 
10, T. D. Limb-girdle M.D. 21 66 667 A. 3.8 - 0.3 A. 4.8 - 0.7 p<0.001 A. 5.6 - 0.5 p <0.001 




MUSCULAR DYSTROPHY PATIENTS 
DETAILS OF DATA ON CARDIAC FUNCTION 
Functional Data; Mean : S.D. 
A. Cardiac Output (CO), L/min 
Treatment B. Stroke Volume (SV) ml/beat 
Patient, - (Days) - C Heart Rate (HR) beats/min - 
No. Sex, Age Diagnosis Ctrl DB2 Oc Control Double Blind Open Q10, crossover. 
C, 83 - 4 C. T2 ... 2 ----- C. 77 - 2 -- 
11. L. L. Myotonic M.D. 27 172 539 A 3.0 - 0.4. A 3.4 - 0.3 n.s. A. 3.7 - 0.4 p <0.01 
(M,38) B. 50 - 7 B. 60 - 4 p C0.01 B. 65 - 5 p(0.001 
C. 61 - 8 C. 58 - 6 - C. 57 7 - 
12. T. E. P. Limb-girdle M.D. 19 120 721 A. 2.7 - 0.6 A. 3.4 - 0.3 p(0.01 A. 3.3 - 0.4 p(0.001 
(M,74) B, 41 - 8 B. S2 4 p(0.01 B. S. - 4 p<0.001 
C, 65 - 2 C. 6S5 - C, 69 - 5 - 
13. M. T. Limb-girdle M.D. 20 150 560 A. 3.2 - 0.5 A, 3.5 - 0.3 n.s. A. 4.9 - 0.9 p(0.001 
(F,69) B. 39 - 6 B. 414 S. B, 56 it 8 p(0.001 
C. 81 - 3 C. 8S - 6 --- C. 87 6 -- 
14. B. H. Welander M.D. 22 75 695 A 3.2 : 0.5 A. 4.6 0.4 pC0.001 A. 4.2 - 0.3 p(0.001 
(F,53) B. 434 B. 62 - 3 p(0.001 B. 55 - 8 p<0.001 
C. 7S 6 C. 74 - 7 - C. 777 - 
S. B. S. Becker's M.D. 31 90 348 A. 8.1 - .2 A. 9.1 - 1.5 n.s. A. 11.1 - 2.5 p <0.001 
(M,15) B. 96 - 11 B. 115 8 p(0.001 B. 130 - 27 p(0.001 
C. 84.5 C. 799 -- C. 84 - 6 -- 
Control 
Double Blind, Coded Period of Study 
Open Period of Study 
TABLE IV 
RESULTS OF DOUBLE BLIND AND OPEN TRIAL 
DATA AND BLOOD DATA 
CoQ10 Blood Levels 
Patient; Double Blind Average ug/ml 
No. Sex, Age Assignment Code Control Blind Crossover 
1. J. A.; M, 8 Placebo Placebo 0.61 0.53 1.62 
2. J. P. B.; M, 43 Placebo Placebo 0.72 0.84 2.48 
3. D. C.; M, 33 Placebo Placebo 0.94 0.75 1.68 
4. D. H.; M., 54 Placebo Placebo 0.89 0.83 0.94 
5. P. K.; F, 31 CoQ10 CoQ10 0.66 2.24 2.84 
6. M. R.; M, 27 CoQ10 CoQ10 0.64 1.05 1.17 
7. M. R.; F, 33 CoQ10 CoQ10 0.74 1.81 1.27 
8. T. A. W.; M., 14. Placebo Placebo 0.81 0.82 1.42 
9. J. M.; F, 58 Placebo Placebo 0.93 1.00 2.05 
10. T. D.; M, 31 CoQ10 CoQ10 1.7 2.74 2.48 
ll. L. L.; M, 3 CoQ10 CoQ10 0.65 1.8S 1.72 
12. T. E. P.; M, 74 CoQ10 CoQ10 04 2.29 2.45 
13. M. T.; F, 69 Placebo Placebo 0.90 0.80 1.70 
14. B. H.; F, 53 CoQ10 CoQ10 0.95 2.20 2.50 
15. B. S.; M, 15 CoQ10 CoQ10 0.58 1.38 1.44 
Mean - S.D. 0.81 - 0.17 p < 0.001 1.85 - 0.56 
What is claimed: or Welander disease, or a closely related disease, said 
1. A method for treating impaired cardiac function of 
human patients having the Duchenne dystrophy, the 
Becker dystrophy, the limb-girdle dystrophies, myo 
tonic dystrophy, Charcot-Marie-Tooth disease fascios- 50 
capulohumoral muscular disease, hypotonia congenitale 
55 
65 
method comprising administering to the patients having 
any one of these dystrophies or myopathies a therapeu 
tically effective amount of a formulation consisting 
essentially of coenzyme Q10. 
k s 
